Trials / Unknown
UnknownNCT04937634
Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an investigator-initiated clinical trial to analysis melphalan pharmacokinetics in pediatric hematopoietic stem cell transplantation patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Melphalan | The subject receives conditioning regimen including melphalan as a part of hematopoietic stem cell transplantation. Dosage of melphalan is 50mg/m\^2/day. Infuse Melphalan over 30 minutes. |
Timeline
- Start date
- 2020-09-11
- Primary completion
- 2023-09-01
- Completion
- 2023-09-01
- First posted
- 2021-06-24
- Last updated
- 2023-02-06
Locations
1 site across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04937634. Inclusion in this directory is not an endorsement.